Media Centre
SynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress
Tuesday October 21, 2025
Read MorePress Releases
SynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate Progress
Tuesday October 21, 2025
SynOx Therapeutics Completes Enrollment in Registrational Phase 3 TANGENT Clinical Trial Significantly Ahead of Timeline
Tuesday August 5, 2025
SynOx Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT)
Monday April 14, 2025
SynOx Therapeutics Announces Board Chair Transition to Align with Advancing Regulatory and Commercialization Strategy
Tuesday April 1, 2025
SynOx Therapeutics Further Strengthens Executive Team with Appointments of U.S.-Based Chief Medical Officer and Chief Commercial Officer
Thursday November 7, 2024
SynOx Therapeutics Adds New Investor and Capital to Series B Financing, Raising Total to $92 Million, and Doses First Patients in Phase 3 Trial
Wednesday October 30, 2024
SynOx Therapeutics secures up to $35m debt financing with Hercules Capital to progress development and commercialisation of emactuzumab
Tuesday April 30, 2024
SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT
Monday April 22, 2024
Emactuzumab designated as an Orphan Medicinal Product in Europe
Wednesday August 31, 2022
SynOx Therapeutics to present two posters at CTOS 2021 virtual Annual Meeting
Friday November 12, 2021
SynOx Therapeutics Further Strengthens Team with Appointments of Chief Medical Officer and Chief Technology Officer
Tuesday August 3, 2021
SynOx Therapeutics Strengthens Team with appointment of Ton Logtenberg as Chairman and Ray Barlow as Chief Executive Officer
Tuesday July 27, 2021
SynOx Therapeutics raises €37M in Series A Financing
Friday December 4, 2020
Publications
Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour
Tuesday December 1, 2020
CSF1R inhibition with emactuzumab in locally advanced diff use-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study
Monday July 13, 2015
